Mirxes Holding Co Ltd
02629
Company Profile
Business description
Mirxes Holding Co Ltd is a miRNA technology company that is making diagnostic solutions for the screening of diseases accessible across its key markets in Asia, including Singapore and China. It has one Core Product (namely, GASTROClearTM), two other commercialized products (namely, LUNGClearTM and FortitudeTM), and six product candidates at the pre-clinical stage, as illustrated in the chart below. GASTROClearTM, its Core Product, is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. The company generates the majority of its revenue from Singapore.
Contact
2 Tukang Innovation Grove
No. 09-02 JTC MedTech Hub
Singapore618305
SGPT: +65 68162931
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
347
Stocks News & Analysis
stocks
Cheap ASX share may have more room to run
Shares are cheap despite rebounding share price, yet risks remain.
stocks
ASX listed media giant drives strong earnings growth
Digital growth drives earnings beat for media share.
stocks
ASX real estate platform outperforms yet questions remain
Valuation remains a key concern despite strong August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,424.10 | 13.30 | -0.14% |
| CAC 40 | 8,722.37 | 7.44 | 0.09% |
| DAX 40 | 26,402.37 | 82.92 | 0.32% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,876.56 | 24.53 | -0.23% |
| HKSE | 25,937.49 | 269.46 | 1.05% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 66,970.22 | 1,363.51 | 2.08% |
| NZX 50 Index | 13,888.24 | 64.11 | 0.46% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,232.60 | 17.00 | -0.18% |
| SSE Composite Index | 3,966.59 | 26.56 | 0.67% |